Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen

被引：9

作者：

Pellegrin, I ^{[1
]}

Garrigue, I

Caumont, A

Pellegrin, JL

Merel, P

Schrive, MH

Bonot, P

Fleury, H

机构：

[1] Bordeaux Univ Hosp, Dept Virol, Bordeaux, France

[2] Bordeaux Univ Hosp, Dept Infect Dis, Bordeaux, France

来源：

关键词：

D O I：

10.1097/00002030-200105250-00022

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：1071 / 1073

页数：3

共 12 条

[1] Batisse D., 1998, AIDS (London), V12, P824
[2] EFFECTS OF DISCONTINUATION OF ZIDOVUDINE TREATMENT ON ZIDOVUDINE SENSITIVITY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES
BOUCHER, CAB
VANLEEUWEN, R
KELLAM, P
SCHIPPER, P
TIJNAGEL, J
LANGE, JMA
LARDER, BA
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (07) : 1525 - 1530
[3] Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
Coakley, EP
Gillis, JM
Hammer, SM
[J]. AIDS, 2000, 14 (02) : F9 - F15
[4] Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001
[5] Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4&lt
[6] 507::AID-JMV14&gt
[7] 3.0.CO
[8] 2-C
[9] The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial
Katlama, C
Clotet, B
Plettenberg, A
Jost, J
Arasteh, K
Bernasconi, E
Jeantils, V
Cutrell, A
Stone, C
Ait-Khaled, M
Purdon, S
[J]. AIDS, 2000, 14 (07) : 781 - 789
[10] Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy
Pellegrin, I
Izopet, J
Reynes, J
Denayrolles, M
Montes, B
Pellegrin, JL
Massip, P
Puel, J
Fleury, H
Segondy, M
[J]. AIDS, 1999, 13 (13) : 1705 - 1709